Physician profile
Eric Anthony Libre
NPI 1710993001
$301,754.17
in general payments reported to CMS, 2019-2025
38 companies · $40K in 2025
The $40K reported for 2025 was more than what 97% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $65K · 2020: $33K · 2021: $41K · 2022: $35K · 2023: $40K · 2024: $48K · 2025: $40K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $100K · Consulting Fee: $14K · Food and Beverage: $7,918 · Travel and Lodging: $5,715 · Education: $376 · Gift: $17.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $99,665.00 |
| Consulting Fee | $13,750.00 |
| Food and Beverage | $7,917.99 |
| Travel and Lodging | $5,714.84 |
| Education | $376.14 |
| Gift | $17.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $211,975.66 | 2019-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $79,107.35 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Janssen Pharmaceuticals, INC | $3,381.60 | 2019-2022 | |
| Genzyme Corporation | $966.41 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $805.44 | 2019-2025 | Dupixent |
| Amgen INC. | $687.60 | 2021-2025 | Tezspire |
| Viiv Healthcare Company | $600.00 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $573.52 | 2019-2025 | Ofev, Jascayd, Spiriva Respimat |
| Genentech USA, INC. | $536.11 | 2019-2023 | Xolair |
| United Therapeutics Corporation | $330.75 | 2019-2023 | Tyvaso |
| Inari Medical, INC. | $313.10 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Insmed, INC. | $280.62 | 2019-2025 | Arikayce |
| Electromed, INC. | $247.31 | 2019-2025 | Smartvest |
| Verona Pharma, INC. | $235.32 | 2025 | Ohtuvayre |
| Actelion Pharmaceuticals US, INC. | $232.67 | 2019-2023 | Uptravi, Opsumit |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $221.31 | 2022-2024 | Prolastin-C Liquid |
| Shionogi INC | $185.10 | 2023-2025 | Fetroja |
| Baxter Healthcare | $125.52 | 2022-2023 | Hillrom - Life 2000 Ventilation System |
| Mylan Specialty L.P. | $112.81 | 2019-2023 | Yupelri |
| Mallinckrodt Hospital Products INC. | $95.48 | 2022-2023 | Acthar |
| Philips North America LLC | $89.94 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $74.89 | 2019-2023 | |
| Circassia INC. | $62.48 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $60.82 | 2022 | |
| Pfizer INC. | $59.61 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $55.17 | 2019-2023 | |
| Gilead Sciences, INC. | $48.81 | 2019 | |
| Vapotherm INC | $40.55 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $38.92 | 2019 | |
| Shire North American Group INC | $33.57 | 2019 | |
| Merck Sharp & Dohme LLC | $28.54 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $26.90 | 2020-2022 | |
| Pulmonx Corporation | $26.68 | 2024 | Zephyr Endobronchial Valve, Chartis Catheter, Zephyr Delivery Catheter |
| Optinose US, INC. | $22.84 | 2022 | |
| Phadia US INC. | $18.81 | 2022 | |
| Sanofi Pasteur INC. | $18.79 | 2019 | |
| Harmony Biosciences LLC | $18.10 | 2020 | |
| Advanced Respiratory, INC | $15.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Libre listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.